ProQR Therapeutics NV
PRQR2.140USD
-0.070-3.17%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
230.50MMarket Cap
LossP/E TTM
More Details of ProQR Therapeutics NV Company
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
ProQR Therapeutics NV Info
Ticker SymbolPRQR
Company nameProQR Therapeutics NV
IPO dateSep 18, 2014
CEOde Boer (Daniel Anton)
Number of employees166
Security typeOrdinary Share
Fiscal year-endSep 18
AddressZernikedreef 9
CityLEIDEN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryNetherlands
Postal code2333 CK
Phone31881667000
Websitehttps://www.proqr.com/
Ticker SymbolPRQR
IPO dateSep 18, 2014
CEOde Boer (Daniel Anton)
Company Executives of ProQR Therapeutics NV
Name
Name/Position
Position
Shareholding
Change
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
-100.00%
Dr. Martin Maier, Ph.D.
Dr. Martin Maier, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Begona Carreno, Ph.D.
Ms. Begona Carreno, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Theresa M. Heggie
Ms. Theresa M. Heggie
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Alison F. Lawton
Ms. Alison F. Lawton
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
-100.00%
Dr. Martin Maier, Ph.D.
Dr. Martin Maier, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Eli Lilly and Company
16.04%
Van Herk Investments
13.60%
Adage Capital Management, L.P.
5.94%
Privium Fund Management BV
4.74%
Affinity Asset Advisors LLC
3.42%
Other
56.26%
Shareholders
Shareholders
Proportion
Eli Lilly and Company
16.04%
Van Herk Investments
13.60%
Adage Capital Management, L.P.
5.94%
Privium Fund Management BV
4.74%
Affinity Asset Advisors LLC
3.42%
Other
56.26%
Shareholder Types
Shareholders
Proportion
Hedge Fund
18.45%
Corporation
16.04%
Family Office
13.60%
Investment Advisor
9.89%
Investment Advisor/Hedge Fund
5.04%
Research Firm
3.13%
Individual Investor
2.00%
Bank and Trust
0.03%
Other
31.83%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
111
41.68M
39.56%
-4.38M
2025Q2
122
61.04M
57.95%
-6.05M
2025Q1
131
62.09M
59.01%
-3.97M
2024Q4
135
61.46M
58.04%
+24.32M
2024Q3
126
39.02M
42.64%
-5.37M
2024Q2
127
38.86M
42.67%
-6.74M
2024Q1
137
38.95M
43.54%
-15.29M
2023Q4
162
39.95M
44.78%
-23.51M
2023Q3
167
40.45M
49.96%
-14.58M
2023Q2
170
45.68M
56.49%
-13.40M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Eli Lilly and Company
16.90M
16.04%
+3.52M
+26.35%
Dec 31, 2024
Van Herk Investments
14.33M
13.6%
+2.13M
+17.44%
Sep 29, 2025
Adage Capital Management, L.P.
6.60M
6.27%
-1.50M
-18.52%
Jun 30, 2025
Privium Fund Management BV
5.00M
4.74%
+11.93K
+0.24%
Jun 30, 2025
Affinity Asset Advisors LLC
3.50M
3.32%
+215.00K
+6.55%
Jun 30, 2025
Morgan Stanley & Co. LLC
3.06M
2.91%
+1.70M
+124.72%
Jun 30, 2025
abrdn Inc.
1.85M
1.76%
--
--
Jun 30, 2025
Sio Capital Management, LLC
2.08M
1.97%
+20.55K
+1.00%
Jun 30, 2025
Kynam Capital Management LP
1.65M
1.57%
-100.54K
-5.75%
Jun 30, 2025
Dafna Capital Management, LLC
1.57M
1.49%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Avantis International Small Cap Equity ETF
0.01%
Avantis International Small Cap Value ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Avantis International Small Cap Equity ETF
Proportion0.01%
Avantis International Small Cap Value ETF
Proportion0%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of ProQR Therapeutics NV?
The top five shareholders of ProQR Therapeutics NV are:
Eli Lilly and Company holds 16.90M shares, accounting for 16.04% of the total shares.
Van Herk Investments holds 14.33M shares, accounting for 13.60% of the total shares.
Adage Capital Management, L.P. holds 6.60M shares, accounting for 6.27% of the total shares.
Privium Fund Management BV holds 5.00M shares, accounting for 4.74% of the total shares.
Affinity Asset Advisors LLC holds 3.50M shares, accounting for 3.32% of the total shares.
Eli Lilly and Company holds 16.90M shares, accounting for 16.04% of the total shares.
Van Herk Investments holds 14.33M shares, accounting for 13.60% of the total shares.
Adage Capital Management, L.P. holds 6.60M shares, accounting for 6.27% of the total shares.
Privium Fund Management BV holds 5.00M shares, accounting for 4.74% of the total shares.
Affinity Asset Advisors LLC holds 3.50M shares, accounting for 3.32% of the total shares.
What are the top three shareholder types of ProQR Therapeutics NV?
The top three shareholder types of ProQR Therapeutics NV are:
Eli Lilly and Company
Van Herk Investments
Adage Capital Management, L.P.
Eli Lilly and Company
Van Herk Investments
Adage Capital Management, L.P.
How many institutions hold shares of ProQR Therapeutics NV (PRQR)?
As of 2025Q3, 111 institutions hold shares of ProQR Therapeutics NV, with a combined market value of approximately 41.68M, accounting for 39.56% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -18.39%.
What is the biggest source of revenue for ProQR Therapeutics NV?
In --, the -- business generated the highest revenue for ProQR Therapeutics NV, amounting to -- and accounting for --% of total revenue.
